Form 4 for RYTM RHYTHM PHARMACEUTICALS, INC.
Accepted 2022-08-23 00:00:00 ET · period of report 2022-08-19 · accession 0001104659-22-093714 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-08-23 | 2022-08-19 | RYTM | Cramer Pamela J. | CHRO | M - OptEx | $19.02 | +13.5K | 15.7K | +607% | +$256.6K |
| D | 2022-08-23 | 2022-08-19 | RYTM | Cramer Pamela J. | CHRO | S - Sale+OE | $24.83 | -13.5K | 2,224 | -86% | -$335.0K |
| D | 2022-08-23 | 2022-08-19 | RYTM | Cramer Pamela J. | CHRO | M - OptEx | $0.00 | -13.5K | 61.5K | -18% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-08-19 | M | A | 13,493 | $19.02 | 15,717 | D | — | — | |
| 2 | Common | Common Stock | 2022-08-19 | S | D | 13,493 | $24.83 | 2,224 | D | — | — | (F1) The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $24.79 to $24.86. The Reporting Person undertakes to provide upon request the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. |
| 3 | Derivative | Stock Option (Right to Buy) | 2022-08-19 | M | D | 13,493 | $0.00 | 61,507 | D | $19.02 · — to 2031-07-25 | 13,493 Common Stock | (F2) The stock options were granted on July 26, 2021. 25% of the shares subject to the option vest and became exercisable on July 26, 2022 and the remaining 75% of the shares subject to the option vest and become exercisable in 12 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer thereafter. |